---
schema_version: "secwatch.filing_event.v1"
accession: "0001689548-24-000098"
form_type: "8-K"
ticker: "PRAX"
cik: "0001689548"
company_name: "Praxis Precision Medicines, Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:38:58.189586+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Praxis Q3 net loss $51.9M; relutrigine seizure freedom; ulixacaltamide interim Q1 2025

## Summary
- Cash and equivalents $411.2M at Sep 30, 2024, up from $81.3M at Dec 31, 2023; net loss $51.9M vs $24.6M prior year Q3.
- Relutrigine (PRAX-562): 46% placebo-adjusted seizure reduction in EMBOLD cohort 1; 30% of patients (5/15) achieved seizure freedom; registrational cohort 2 initiated.
- Ulixacaltamide: interim analysis for Phase 3 Essential3 Study 1 expected Q1 2025; NDA filing anticipated in 2025; Parkinson's program to re-initiate.
- Vormatrigine (PRAX-628): RADIANT topline in H1 2025 and POWER1 topline in H2 2025; pain expansion being evaluated.
- R&D expenses $41.9M (up $24.6M); G&A $15.3M (up $6.6M); stock-based compensation $12.4M.

## SEC filing metadata
- accession: 0001689548-24-000098
- form_type: 8-K
- ticker: PRAX
- cik: 0001689548
- company_name: Praxis Precision Medicines, Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689548/000168954824000098/0001689548-24-000098-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689548/000168954824000098/prax-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689548-24-000098
- JSON: https://secwatch.observer/filing/0001689548-24-000098.json
- Plain text: https://secwatch.observer/filing/0001689548-24-000098.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.